logo
Plus   Neg
Share
Email

Genentech: Tecentriq Fails To Meet Primary Endpoint In Phase III Study

Genentech, a member of the Roche Group (RHHBY), reported that the Phase III IMvigor010 study evaluating Tecentriq as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival compared to observation in people with muscle-invasive urothelial cancer.

Genentech noted that, in addition to ongoing Phase III studies in early and advanced bladder cancer, the company has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across genitourinary, skin,
breast, gastrointestinal, gynecological and head and neck cancers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla said it will produce ventilators at its Gigafactory in Buffalo, New York to support the city's hospitals amid the coronavirus pandemic. New York is the worst affected state in the U.S. Last Saturday, Musk tweeted that he "had a long engineering discussion with Medtronic about state-of-the-art ventilators. Luxury fashion house Ralph Lauren will donate $10 million to help fight the coronavirus pandemic and manufacture face masks as well as medical gowns in the U.S. The company's charity arm, the Ralph Lauren Corporate Foundation, said in a statement that it is committing $10 million towards the global response to the COVID-19 pandemic. General Motors Co. is delaying work on new vehicle models and is cutting pay for its executives as part of efforts to conserve cash amid the coronavirus or Covid-19 pandemic. The automotive giant also extended the shutdown of North American plants indefinitely. Multiple reports cited an internal memo that salaried workforce will have 20 percent of pay deferred starting April 1.
Follow RTT
>